Amer Zeidan, MD

Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.

Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.

Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.

Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.

Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.

A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.

Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.

Experts consider shortcomings in the identification and management of myelodysplastic syndromes.

Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.

Expert perspectives on the changes in MDS subclassifications as understandings of the disease have evolved.

Shared insight on how to best educate patients and caregivers on the broad nature of myelodysplastic syndromes.

A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications.